New drug BL-M07D1 targets Hard-to-Treat HER2 cancers in early trial
NCT ID NCT06293898
First seen Nov 05, 2025 · Last updated Jun 20, 2026 · Updated 31 times
Summary
This early-stage trial is testing a new drug called BL-M07D1 in 280 adults with advanced solid tumors that have a protein called HER2. The cancers include breast, lung, stomach, and others that have not responded to at least two prior treatments. The study aims to find a safe dose and check for early signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars Sinai
RECRUITINGLos Angeles, California, 90211, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Georgia Cancer Center at Augusta University
RECRUITINGAugusta, Georgia, 30912, United States
Contact Email: •••••@•••••
Contact
-
Karmanos Cancer Institiute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NYU Langone Hospital - Long Island Investigational Pharmacy
RECRUITINGMineola, New York, 11501, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oncology Consultants
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-••••
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213, United States
Contact Email: •••••@•••••
Contact
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon Research institute - Lake Nona Florida
RECRUITINGOrlando, Florida, 32827, United States
Contact
-
Scripps Health
NOT_YET_RECRUITINGSan Diego, California, 92121, United States
Contact Email: •••••@•••••
Contact
-
University of Alabama Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago Medicine
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
Contact
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M07D1 (a drug given by IV infusion every 3 weeks)
What this could lead to
If successful, this could point toward a new treatment option for several advanced cancers that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug works. Side effects and lack of efficacy are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.